Umbilical Cord Mesenchymal Stem Cells Increase Expansion of Cord Blood Natural Killer Cells

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 9, 2008, Pages 1031-1038

  Boissel, Laurent ^a   Tuncer, Hande H ^a   Betancur, Monica ^a   Wolfberg, Adam ^a   Klingemann, Hans ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Cord blood; Cytotoxicity; Mesenchymal stem cells; NK cell

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; FLT3 LIGAND; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 3; MESSENGER RNA;

ARTICLE; CELL ACTIVATION; CELL COUNT; CELL DEATH; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; ELECTROPORATION; EX VIVO STUDY; FEMALE; FREEZE THAWING; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; RADIATION EXPOSURE; RAJI CELL; RELIABILITY; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

ANTIGENS, CD; CELL COMMUNICATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; FETAL BLOOD; GRAFT VS HOST DISEASE; HUMANS; IMMUNITY, CELLULAR; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA; MEMBRANE PROTEINS; MESENCHYMAL STEM CELLS; RECURRENCE; UMBILICAL CORD;

EID: 49449099583     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.06.016     Document Type: Article

References (33)

1. Klingemann H.-G. Relevance and potential of natural killer cells in stem cell transplantation. Biol Blood Marrow Transplant 6 (2000) 90-99
2. Farag S.S., VanDeusen J.B., Fehniger T.A., and Caligiuri M.A. Biology and clinical impact of human natural killer cells. Int J Hematol 78 (2003) 7-17
3. Arai S., and Klingemann H.-G. Natural killer cells: can they be useful as adoptive immunotherapy for cancer?. Expert Opin Biol Ther 5 (2005) 163-172
4. Vivier E., Tomasello E., Baratin M., Walzer T., and Ugolini S. Functions of natural killer cells. Nat Immunol 9 (2008) 503-510
5. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
6. Ruggeri L., Cappani M., Casacci M., et al. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Blood 94 (1999) 333-339
7. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
8. Schoemans H., Theunissen K., Maertens J., Boogaerts M., Verfaillie C., and Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 38 (2006) 83-93
9. Brunstein C.G., Baker K.S., and Wagner J.E. Umbilical cord blood transplantation for myeloid malignancies. Curr Opin Hematol 14 (2007) 162-169
10. Hofmeister C.C., Zhang J., Knight K.L., Le P., and Stiff P.J. Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplant 39 (2007) 11-23
11. Yu H., Fehniger T.A., Fuchshuber P., et al. Flt-3 ligand promotes the generation of a distinct CD34 human natural killer cell progenitor that responds to interleukin-15. Blood 92 (1998) 3647-3657
12. Jacobsen S.E.W., Okkenhaug C., Myklebust J., Veiby O.P., and Lyman S.D. The Flt-3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 181 (1995) 1357-1363
13. - cells and maintain progenitor cells in vitro. Blood 87 (1996) 3563-3570
14. Dalle J.H., Menezes J., Wagner E., et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res 57 (2005) 649-655
15. Xing D., Fang W., Decker W.K., and Li S. Ex vivo expansion of cord blood NK cell have in vivo efficacy against leukemia. Blood 110 (2007) 805a
16. - cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 180 (1997) 132-139
17. Wang H.S., Hung S.C., Peng S.T., et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 22 (2004) 1330-1337
18. Pittinger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
19. Friedman R., Betancur M., Boissel L., Tuncer H., Cetrulo C., and Klingemann H. Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biol Blood Marrow Transplant 13 (2007) 1477-1486
20. Lu L.L., Liu Y.J., Yang S.G., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91 (2006) 1017-1026
21. Weiss M.L., Medicetty S., Bledsoe A.R., et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 24 (2006) 781-792
22. Mitchell K.E., Weiss M.L., Mitchell B.M., et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 21 (2003) 50-60
23. Mueller T., Uherek C., Maki G., et al. Expression of a CD20-specific antigen receptor enhances activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57 (2008) 411-423
24. Freud A.G., and Caligiuri M.A. Human natural killer cell development. Immunol Rev 214 (2006) 56-72
25. Imai C., Iwamoto S., and Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106 (2005) 376-383
26. Uherek C., Tonn T., Herrmann B., et al. Retargeting of NK-cell cytolytic activity to ErbB2 expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100 (2002) 1265-1273
27. Boissel L., Betancur M., Tuncer H., Weitzman J., and Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores natural killer cell mediated killing of CLL cells. Blood 110 (2007) 915a
28. Condiotti R., Zakai Y.B., Barak V., and Nagler A. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Exp Hematol 1 (2001) 104-113
29. Gada P., Gleason M., McCullar V., McGlave P.B., and Miller JS. Optimal NK cell expansion depends on accessory cells, synergy between physiologic concentrations of IL-2 and IL-15, and umbilical cord blood (UCB) NK cell precursors expand better than adult NK cells. Blood 108 (2006) 1040a
30. Klingemann H.-G., Eaves C.J., Barnett M.J., et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 14 (1994) 389-396
31. Saito S., Ugai H., Sawai K., et al. Isolation of embryonic stem-like cells from equine blastocysts and their differentiation in vitro. FEBS Lett 531 (2002) 389-396
32. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., and Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006) 1484-1490
33. Su S., Muthalagu R., Nguyen D.M., et al. Effective and stable gene transfer into human NK cells using an HIV-1-based lentiviral vector system. Mol Ther 16 (2008) S286